Background: Topical β-blockers, propranolol, and timolol were used for pyogenic
granuloma (PG) treatment; however, their efficacies and safety profiles were not
compared.
Aims: The aim was to evaluate the safety and efficacy of propranolol 1% and timolol
0.5% creams in the treatment of pyogenic granulomas.
Patients: The study included 30 PG patients. They were divided into three groups
(10 patients each). Group I patients received propranolol 1% cream. Group II patients
used timolol 0.5% l cream. Group III patients used placebo cream. Creams were applied
twice daily for 2 months. Patients were followed up for 3 months to detect any
recurrence.
Results: Complete resolution was reported in 6 patients of groups I and II, while none
of the control patients reported complete resolution. Despite the absent change in
lesions' size in 40% of β-blockers treated groups, they all reported decreased bleeding
tendency. There was insignificant difference between the clinical responses between
β-blockers groups. No recurrence was reported in any of the patients who
achieved complete resolution after 3 months of follow-up. Younger patients respond
better to β-blockers. Three patients were deteriorated on beta-blockers treatment.
Conclusion: β-blockers are a promising PG treatment option in cases where invasive
modalities are not desirable especially in younger patients